EDC validation is one of the most consistently misunderstood aspects of clinical data management. Some teams treat it as a documentation exercise to be completed at study start and forgotten. Others conflate vendor qualification with study-specific validation. Getting this wrong creates audit findings, data integrity questions, and — in worst cases — questions about the reliability of an entire dataset.
This guide explains what EDC validation actually requires, how it differs from vendor qualification, and what documentation your team needs to produce and maintain throughout the study lifecycle. For a broader view of what EDC systems are and how they capture data, see our pillar article.
What Is EDC Validation in Clinical Trials?
In the clinical trial context, Electronic Data Capture validation refers to the process of establishing documented evidence that a computer system — specifically the EDC platform configured for a particular study — consistently does what it is intended to do. The goal is to ensure that data collected, stored, and processed by the system is accurate, reliable, and traceable.
Validation is required because clinical trial data forms the basis for regulatory decisions about drug safety and efficacy. Regulatory agencies including the FDA and EMA require that computerised systems used in clinical trials meet defined standards for electronic records and electronic signatures, and that sponsors can demonstrate through documentation that these standards have been met.
Importantly, there are two distinct but related validation activities that must be kept separate: vendor qualification (confirming that the underlying EDC platform meets regulatory requirements) and study-specific validation (confirming that the specific configuration of that platform for your study works as intended).
Regulatory Framework for EDC Validation
FDA 21 CFR Part 11
For clinical trials destined for FDA submission, 21 CFR Part 11 — Electronic Records; Electronic Signatures — is the primary regulatory framework governing EDC systems. Part 11 establishes requirements for:
- Audit trails: Computer-generated, date- and time-stamped records of when records are created, modified, or deleted. The original entry and each subsequent change must be preserved, along with the identity of the person making the change and the date and time. The principles of audit trail design in modern EDC platforms sit at the core of every Part 11-compliant system.
- Access controls: Systems must limit access to authorised users through unique usernames and passwords or equivalent authentication. Access privileges should reflect the user's role in the study.
- Electronic signatures: Signatures must be linked to their respective electronic records and cannot be reused or reassigned to another individual.
- System controls: Including automatic logoff after a period of inactivity, authority checks before system operations, and device checks for data input validity.
FDA guidance on Part 11 acknowledges a risk-based approach — the rigor of validation documentation should be proportional to the impact of the system on data integrity and patient safety. Commercial, off-the-shelf EDC systems used for Phase II-IV studies generally represent moderate to high risk and require thorough validation documentation.
ICH E6 (R2) GCP
The ICH E6 (R2) Good Clinical Practice guideline (and the updated ICH E6 (R3) guidance) addresses computerised systems used in clinical trials. Section 5.5 of ICH E6 (R2) requires that validated, SOP-driven systems be used for data handling, and that any modification to those systems be validated prior to implementation. The guidance also requires that the source data be attributable, legible, contemporaneous, original, and accurate — principles often summarised as ALCOA. EDC validation contributes directly to demonstrating ALCOA compliance.
GAMP 5
While not a regulatory requirement, the GAMP 5 framework (Good Automated Manufacturing Practice, 5th edition) from ISPE provides widely adopted industry guidance for computerised system validation. GAMP 5 categorises software by type and recommends proportionate validation approaches:
- Category 1: Infrastructure software (operating systems, database engines) — requires configuration records, not full validation
- Category 3: Non-configured software (commercial software used as-is) — requires testing of the operational environment
- Category 4: Configured software — requires configuration specification and testing of configured functions
- Category 5: Custom software — requires full lifecycle validation including design specifications and code review
Commercial EDC systems like Medidata Rave, Oracle Clinical One, and Veeva Vault EDC typically fall into Category 4 when configured for a specific study. This means the sponsor's validation responsibility focuses on the configured elements — the CRF design, edit checks, and user roles — rather than the underlying software code, which is the vendor's responsibility to qualify. For a comparison of these and other platforms, see our guide to top EDC vendors.
The Difference Between Vendor Qualification and Study Validation
This distinction is fundamental and frequently confused.
Vendor qualification (sometimes called platform qualification or IQ/OQ at the platform level) is the vendor's responsibility. A reputable commercial EDC vendor maintains documentation demonstrating that their platform is installed correctly and operates according to its specifications. This typically includes:
- Installation Qualification (IQ): Evidence that the system is installed in its intended environment according to vendor specifications
- Operational Qualification (OQ): Evidence that the system operates correctly throughout its intended operating ranges
Sponsors and CROs should request and review the vendor's IQ/OQ documentation as part of vendor selection and qualification. The selection process itself — whether for a single trial or across your clinical programme — is covered in our guides to trial-level EDC selection and company-level platform strategy. However, vendor documentation does not replace study-specific validation.
Study-specific validation is the sponsor's or CRO's responsibility. It demonstrates that the specific configuration of the EDC system for a particular study — the CRF pages, field definitions, edit checks, branching logic, user roles, and workflows — functions as intended. This is where validation effort is most commonly underestimated.
What Study-Specific EDC Validation Requires
A complete study-specific EDC validation package typically includes:
Study Specifications (the eCRF / EDC Specification)
In practice, the study-specific requirements that guide EDC validation are rarely captured in a single URS and a single Functional Specification. They are typically documented across a set of related specifications, often referred to collectively as the eCRF specification or EDC specification. Together, these documents play the role that a classical URS and FS would play in general computer system validation — they define both what the configured system must do for the study and how it will do it. A typical package includes:
- eCRF screen (page) specifications — defining the layout, fields, data types, and behaviour of each form, page, and visit.
- Data validation plan or edit check plan — defining edit checks, consistency rules, and data quality logic.
- Data transfer or export specifications — defining the structure, format, frequency, and content of any data exports or system-to-system integrations.
- User role and privilege definitions — defining which roles can view, enter, query, or sign data.
- Reports and alerts specifications — defining the standard reports and automated alerts required for the study.
Together, these documents form the reference against which all subsequent study-specific validation testing is designed and traced. They are typically developed iteratively with input from data management, trial management, statistics, medical, and site representatives, and should be approved before build and testing begins.
Testing: Unit Testing and User Acceptance Testing (UAT)
Testing of the configured study-specific EDC is typically split into two complementary activities, each with a distinct purpose and method: unit testing and user acceptance testing (UAT). A common pitfall is to blur these together — either by skipping technical testing and expecting UAT to find configuration errors, or by having UAT simply repeat the developer's technical checks. The two activities should be kept distinct.
Unit Testing (Technical Test)
Unit testing is performed by the eCRF developer as part of the build process. It confirms that each configured unit — every field, option, dropdown, edit check, dynamic behaviour, role setting, and export element — matches the corresponding specification. Unit testing aims for close to 100% coverage of the configuration; a risk-based approach leaning on standard components or library items can justifiably reduce coverage, but the focus remains on a piece-by-piece match against the specifications.
User Acceptance Testing (UAT)
UAT is complementary to, not a repetition of, unit testing. It is scenario-driven and takes a holistic, user-oriented view. Rather than confirming that each individual element matches its spec, UAT confirms that (a) the configured eCRF matches the protocol and the intent of the protocol, and (b) the eCRF is feasible in a real-life clinical site setting. UAT does not need to exercise 100% of the configuration; it focuses on realistic patient journeys and on "what can go wrong" scenarios. For this reason, UAT is typically managed by data management and should include input — or direct participation — from trial management, medical, statistics, and site representatives.
Test execution is documented for both unit testing and UAT — recording the expected result, actual result, pass/fail status, and tester identity — and any discrepancies are tracked through to resolution.
Typical UAT scenarios include:
- Correct display and behaviour of each CRF page, field, and visit in the context of a realistic patient journey
- Edit check behaviour in context (confirming each edit check fires correctly on realistic data and does not fire on valid data)
- End-to-end data flow from entry through to export and, where applicable, downstream systems
- Data export format and content against the export specification
Testing of Critical EDC System Functionalities
In addition to the study-specific validation described above, it is good practice to also test a defined set of critical EDC system functionalities as part of each study-specific validation — even when these functionalities are implemented at system level and have already been validated by the vendor and verified through vendor qualification. Testing them in the study context confirms that the study configuration has not inadvertently altered their behaviour, and provides contemporaneous evidence for the specific study. These functionalities typically include:
- Query generation and resolution workflow
- Role-based access restrictions (confirming users can only see and do what their role permits)
- Audit trail capture (confirming that all changes are captured with correct user and timestamp)
- Electronic signature functionality
Traceability Matrix
The traceability matrix links each requirement — as defined in the eCRF/EDC specification package — to its corresponding unit test and UAT test scripts. This document demonstrates that every requirement has been tested and provides evidence of complete validation coverage.
Validation Summary Report
The validation summary report documents the outcome of the validation activities, confirms that UAT was completed satisfactorily (or describes how any defects were resolved), and provides a formal conclusion that the system is suitable for use in the study.
Change Control During the Study
Validation is not a one-time activity. Any change to the EDC configuration during the study — adding CRF pages, modifying edit checks, changing user role definitions — requires formal change control and, depending on the scope of the change, additional validation testing before the change is implemented in the production environment.
A robust change control process for EDC systems includes:
- Formal change request documentation describing the change and its rationale
- Impact assessment identifying what system functions may be affected
- Test scripts covering the changed functionality and any potentially affected areas
- Documented test execution and approval before production implementation
- Updated validation documentation reflecting the change
Undocumented or insufficiently tested mid-study changes are among the most common EDC-related audit findings. Regulatory inspectors routinely review change control records as part of data integrity assessments.
Common EDC Validation Mistakes
Relying entirely on vendor documentation. The vendor's platform qualification documents support your validation — they do not replace it. Study-specific configuration testing is always required.
Writing test scripts after testing. Test scripts should be written before execution, based on the design specification, and approved before UAT begins. Retrospective scripting undermines the integrity of the validation record.
Insufficient negative testing. Validation testing must confirm that edit checks do not fire when they should not, not only that they fire when they should. Missing negative tests creates false confidence in system behaviour.
Poor change control. Mid-study configuration changes implemented without formal change control and documented testing are a primary source of data integrity audit findings.
Conflating UAT for one study with validation for another. Each study configuration is distinct. Validation documentation from a previous study on the same platform does not satisfy the validation requirement for a new study with a different configuration.
EDC Validation and TriTiCon Training
Understanding the principles behind EDC validation — why it is required, what it must demonstrate, and how it connects to data integrity and regulatory compliance — is essential for clinical data managers working on any regulated study. TriTiCon's clinical data management training builds this foundational understanding of the regulatory and process principles that govern EDC use throughout the study lifecycle. Effective user training is also a critical complement to validation — a validated system still depends on trained users to produce quality data.
Explore the TriTiCon course platform and free resources.
Frequently Asked Questions
Is EDC validation required by the FDA?
Yes. 21 CFR Part 11 requires that electronic systems used to create, modify, maintain, or transmit clinical trial records meet defined standards and that validation evidence is maintained. FDA inspection readiness requires complete, contemporaneous validation documentation.
How long should EDC validation documentation be retained?
Validation documentation is part of the study's essential documents and must be retained for at least two years after the last approval of a marketing application in an ICH region, or two years after the study is discontinued, whichever is later. Many sponsors retain study documentation for longer periods.
What is User Acceptance Testing (UAT) in EDC validation?
UAT is scenario-driven, user-oriented testing of the study-specific EDC configuration, confirming that the system matches the protocol and is feasible for real-life site use. It complements unit (technical) testing, which is performed by the eCRF developer during build and confirms that each configured element matches its specification. Together, unit testing and UAT provide the evidence that the configured EDC system meets both its technical specification and the study's real-world requirements.
Who is responsible for EDC validation — the vendor or the sponsor?
Both have responsibilities. The vendor is responsible for qualifying their platform. The sponsor (or CRO acting on the sponsor's behalf) is responsible for study-specific validation demonstrating that the configured system meets the study's requirements. Sponsor responsibilities cannot be fully delegated to the vendor.
What happens if an EDC system fails during a study?
System failures during a study must be documented and assessed for impact on data integrity. Depending on the nature and duration of the failure, data collected during the affected period may require additional review. Incident records should be maintained as part of the study's essential documents.
Last Updated: May 2026
This article reflects general industry principles. Specific regulatory requirements should be verified against current FDA, EMA, and ICH guidance documents, including 21 CFR Part 11, ICH E6 (R3), and applicable GAMP guidance.
This article is part of TriTiCon's USA Technology content series on clinical data management.
Related articles:
- Complete Guide to EDC Systems in Clinical Trials 2026
- EDC vs Paper CRFs: A Complete Comparison for Clinical Trials
- Top EDC Vendors 2026: Choosing the Right Platform
- EDC System Selection Guide: Trial-by-Trial Approach
- EDC System Selection Guide: Company-Level Platform Strategy
- EDC User Training Best Practices for Clinical Trial Sites
